COMMUNIQUÉS West-GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
14/03/2018
Initiated final testing of safety and efficacy in non-human primates (NHP) for our lead program intended to treat patients with transthyretin amyloidosis (ATTR) Completed successful knockout editing in mice of the [...]
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
14/03/2018
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or serious conditions with [...]
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
14/03/2018
SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
14/03/2018
VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and Friedreich’s ataxia [...]
Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference
14/03/2018
Summit Therapeutics plc ("Summit" or the "Company") Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference Oxford, UK, and Cambridge, MA, US, 14 March 2018 - Summit [...]
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference
14/03/2018
YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX ), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life [...]
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases
14/03/2018
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]
Easton Pharmaceuticals Announces It Has Commenced Negotiations With An AMPR Applicant Towards a Marijuana Cultivators / Growers License For Canada; Provides iBliss Update
14/03/2018
TORONTO, ON, March 14, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has commenced negotiations with an AMPR applicant towards a Canadian Marijuana cultivators / growers license. Provides [...]
Nabriva Therapeutics to Present at the Needham and Company 17th Annual Healthcare Conference
14/03/2018
DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV ), a clinical stage biopharmaceutical company engaged in the research and development of novel anti- [...]
BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
14/03/2018
RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI ), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that [...]
Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference
14/03/2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) highlighted the rigour being utilised in the collection and analysis of muscle biopsies [...]
Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
14/03/2018
ALPHARETTA, Ga., March 14, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases [...]
Cesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) Services
14/03/2018
RANCHO CORDOVA, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ: KOOL ), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today [...]
Olainfarm will hold Fourth Quarter 2017 Investor Conference Webinar
14/03/2018
Olaine, 2018-03-14 11:10 CET (GLOBE NEWSWIRE) -- Webinar will be hosted by the Member of the Management Board Salvis Lapiņš. The presentation will be held in English. During the webinar Salvis Lapiņš will inform about [...]
Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
14/03/2018
Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology IP position strengthened in the U.S. Patent supports utility of Unyvero Lysator Technology for sample preparation Amsterdam, the [...]
Bio-on launches U-COAT, a company operating in the fertilisers market with a biodegradable controlled-release solution.
14/03/2018
The new company, U-COAT S.p.A. , will sell an innovative solution for the controlled release of Urea fertilisers into the soil. The innovation was developed by Bio-on with PHAs bioplastics, so it is 100% natural and [...]
Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference
14/03/2018
Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference Amsterdam, The Netherlands, March 14, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: [...]
DBV Technologies Reports Full Year 2017 Financial Results
14/03/2018
Montrouge, France, March 14, 2018 DBV Technologies Reports Full Year 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced full year 2017 results. Audit [...]
Résultats Financiers 2017 de DBV Technologies
14/03/2018
Montrouge, France, le 14 mars 2018 (7h30 CET) Résultats Financiers 2017 de DBV Technologies DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - NASDAQ : DBVT), société biopharmaceutique française, a annoncé aujourd [...]

Pages